NCT05306912Active, not recruiting
Molecular Analysis of Endoscopic Cytology Samples Supernatant in Pulmonary Nodules
Molecular Analysis of Endoscopic Cytology Samples Supernatant in Pulmonary Nodules (Cancer Or Benign Endoscopy) (KOBE)
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
Lung cancer screening is based on low dose CT scan (LDCT), a highly sensitive but poorly specific tool. Complementary specific approaches are thus strongly needed, among which cell-free DNA (cfDNA) genotyping has been proven highly specific but of low sensitivity (25 to 50% for stage I diseases) due to inconstant tumor shed. Tumor biopsy is thus often required and radial endobronchial ultrasound (rEBUS) bronchoscopy is a minimally invasive approach (\<3% complications) but of limited sensitivity in cases of nodules \< 20 mm. The investigators hypothesized that methylation analysis on cfDNA floating in supernatant derived from rEBUS specimens could improve rEBUS sensitivity
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 1 Mar 2022
- Start date
- 8 Apr 2022
- Primary completion date
- Sept 2027
- Lead sponsor
- University Hospital, Toulouse
- Diseases
- Lung cancer
- NCT number
- NCT05306912
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 8 Apr 2022 to the primary completion date, Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Lung cancer diagnosed before the date of the procedure
- Lung cancer strongly suspected due to mediastinal or extra thoracic lesions
Other
- Patient under State Medical Assistance
- Patient deprived of liberty on administrative or judicial decision, or patient under guardianship, curators or safeguard of justice
Who the study is looking for
- rEBUS bronchoscopy planned for one, two or three ≤ 20 mm nodule
- World Health Organization (WHO) Performance status 0-3
- Informed signed consent
- Patient affiliated or beneficiary of a social security scheme (Social Security or Universal Medical Coverage).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Toulouse University Hospital Coordinator of this site? Confirm its status | Toulouse | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.